Aptadir Therapeutics

Aptadir Therapeutics S

Biotech & Life Sciences

Sector

Biotechnology

Model

01Company Overview

Aptadir Therapeutics S.R.L. develops biotechnology solutions focused on RNA therapeutics to reprogram DNA methylation. The Company conducts preclinical research and drug discovery for oncology indications and rare diseases.

02Backed By4 investors

4C4BIO Capital→AVAngelini Ventures→

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

CVCDP Venture Capital→

CCE-Ventures→

03Recent Activity

FROM 4BIO Capital

4BIO Capital led a €40M ($45M) seed round in Aptadir Therapeutics, which is developing first-in-class RNA inhibitors (DNMTs Interacting RNAs / DiRs) to reverse aberrant DNA methylation for genetic disorders including Fragile X Syndrome.

INVESTMENT·4biocapital.com

SEP 29, 2026

FROM CDP Venture Capital

CDP Venture Capital (via Digital Transition Fund and EXTEND) participated in Aptadir Therapeutics' €40M seed round for RNA inhibitor-based therapeutics.